

LIST OF TABLES.

Table no.	Title	Page no.
2.1	Commercially FDA approved MRI contrast agents.	17
2.2	Examples of targeted molecules for treatment of glioblastoma.	19
2.3	Nanoformulations based delivery of lenalidomide.	22
2.4	Current status of formulations of iron oxide for diagnosis and therapy.	33
3.1	Data of calibration curve of lenalidomide in Methanol: Acetonitrile.	41
3.2	Precision of the analytical method.	43
3.3	Results of accuracy test.	43
3.4	Data of calibration curve of lenalidomide in methanolic PBS pH 7.4.	46
3.5	Data of bio analytical method.	50
4.1	Composition of the standard and test solutions for florescamine assay.	60
4.2	Observations of the solvothermal method with oleic acid as surfactant.	64
4.3	Optimization of reaction parameters for polyol process.	67
4.4	Optimization of drug coating on metallic core.	70
5.1	Composition of gelatin MRI phantoms.	75
5.2	Quantitative results of EDAX analysis of metallic nanoparticles.	81
5.3	Analysis of XRD peaks of iron oxide, gadolinium doped iron oxide and gadolinium oxide nanoparticles.	82
5.4	Analysis of peak area of GC for residual solvent analysis.	88
5.5	Release kinetics of Plain drug suspension, drug coated core and theranostic nanoparticles.	91
6.1	Reference values for the hemolysis as per ASTM E254-08 guidelines.	110
7.1	Group of animals for <i>in vivo</i> biodistribution.	113
7.2	Bio distribution of radiolabelled theranostic nanoparticles in Wistar rats.	116